GLP-1, a powerful physiological incretin: an update
Food intake, especially carbohydrates, release incretin, which is an endocrine transmitter. Among the various endocrine modulators, Glucagon-like peptide 1 (GLP-1) is more effective in stimulating the release of insulin and more powerful regulator of physiological functions. Mainly (GLP-1) receptors...
Gespeichert in:
Veröffentlicht in: | Journal of biological regulators and homeostatic agents 2018-09, Vol.32 (5), p.1171-1176 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1176 |
---|---|
container_issue | 5 |
container_start_page | 1171 |
container_title | Journal of biological regulators and homeostatic agents |
container_volume | 32 |
creator | Malik, J Roohi, N |
description | Food intake, especially carbohydrates, release incretin, which is an endocrine transmitter. Among the various endocrine modulators, Glucagon-like peptide 1 (GLP-1) is more effective in stimulating the release of insulin and more powerful regulator of physiological functions. Mainly (GLP-1) receptors are expressed in lungs, α and β cells of pancreatic islets and the nervous system. Peripheral tissues, gastrointestinal tract and extra pancreatic tissues i.e., vascular smooth muscle, kidney and heart, also contain high affinity receptors for GLP-1. The aim of this systematic review was to gather the available published evidence of the functions performed by GLP-1 through the activation of its receptor in various organs. This review suggest that GLP-1 receptor signaling helps prevent beta cell apoptosis and conserve function and morphology of human islet. The effect of GLP-1 signaling in weight loss in diabetic patients was proved by previous studies. The long term use of GLP-1 receptor agonists reduces cardiovascular and renal complications in diabetic patients. Significant evidence was found in previous literature for its effect on pancreatic secretions. The secretions of many enzymes and hormones, such as trypsin, lipase and glucagon, inhibited significantly while the increase in levels of insulin and somatostatin was reported in many studies. GLP-1 has a prominent role in cardiac functioning and increases the heart rate considerably. Based on the vast impact of GLP-1 on physiological functions, many GLP-1 receptor agonists can be made that can increase the healthy life span. |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2122578433</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2122578433</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-cf2c6a70a1b063f3a9e562a96add4881ee584a09cbae4d2ac8ebbdc50022f2173</originalsourceid><addsrcrecordid>eNo1j01LxDAUAHNQ3HX1L0iOHiwkeWnTeJNFd4WCHhS8ldfkVSP9iE2L7L9XcD3NZRiYE7YWYCGzRr-t2HlKn0Jo0MacsRUIAK2FXTPYVc-ZvOHI4_hNU7t0PH4cUhi78T047HgY3ERzGG45DnyJHme6YKctdokuj9yw14f7l-0-q552j9u7KotKyjlzrXIFGoGyEQW0gJbyQqEt0HtdlpIoLzUK6xok7RW6kprGu1wIpVolDWzY9V83TuPXQmmu-5AcdR0ONC6pVlKp3JQa4Fe9OqpL05Ov4xR6nA71_yj8ABRITSU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2122578433</pqid></control><display><type>article</type><title>GLP-1, a powerful physiological incretin: an update</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Malik, J ; Roohi, N</creator><creatorcontrib>Malik, J ; Roohi, N</creatorcontrib><description>Food intake, especially carbohydrates, release incretin, which is an endocrine transmitter. Among the various endocrine modulators, Glucagon-like peptide 1 (GLP-1) is more effective in stimulating the release of insulin and more powerful regulator of physiological functions. Mainly (GLP-1) receptors are expressed in lungs, α and β cells of pancreatic islets and the nervous system. Peripheral tissues, gastrointestinal tract and extra pancreatic tissues i.e., vascular smooth muscle, kidney and heart, also contain high affinity receptors for GLP-1. The aim of this systematic review was to gather the available published evidence of the functions performed by GLP-1 through the activation of its receptor in various organs. This review suggest that GLP-1 receptor signaling helps prevent beta cell apoptosis and conserve function and morphology of human islet. The effect of GLP-1 signaling in weight loss in diabetic patients was proved by previous studies. The long term use of GLP-1 receptor agonists reduces cardiovascular and renal complications in diabetic patients. Significant evidence was found in previous literature for its effect on pancreatic secretions. The secretions of many enzymes and hormones, such as trypsin, lipase and glucagon, inhibited significantly while the increase in levels of insulin and somatostatin was reported in many studies. GLP-1 has a prominent role in cardiac functioning and increases the heart rate considerably. Based on the vast impact of GLP-1 on physiological functions, many GLP-1 receptor agonists can be made that can increase the healthy life span.</description><identifier>ISSN: 0393-974X</identifier><identifier>PMID: 30334409</identifier><language>eng</language><publisher>Italy</publisher><subject>Diabetes Complications - drug therapy ; Diabetes Complications - metabolism ; Diabetes Complications - prevention & control ; Diabetes Mellitus - drug therapy ; Diabetes Mellitus - metabolism ; Glucagon-Like Peptide 1 - physiology ; Glucagon-Like Peptide-1 Receptor - metabolism ; Humans ; Incretins - physiology ; Insulin-Secreting Cells - cytology ; Insulin-Secreting Cells - metabolism</subject><ispartof>Journal of biological regulators and homeostatic agents, 2018-09, Vol.32 (5), p.1171-1176</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30334409$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Malik, J</creatorcontrib><creatorcontrib>Roohi, N</creatorcontrib><title>GLP-1, a powerful physiological incretin: an update</title><title>Journal of biological regulators and homeostatic agents</title><addtitle>J Biol Regul Homeost Agents</addtitle><description>Food intake, especially carbohydrates, release incretin, which is an endocrine transmitter. Among the various endocrine modulators, Glucagon-like peptide 1 (GLP-1) is more effective in stimulating the release of insulin and more powerful regulator of physiological functions. Mainly (GLP-1) receptors are expressed in lungs, α and β cells of pancreatic islets and the nervous system. Peripheral tissues, gastrointestinal tract and extra pancreatic tissues i.e., vascular smooth muscle, kidney and heart, also contain high affinity receptors for GLP-1. The aim of this systematic review was to gather the available published evidence of the functions performed by GLP-1 through the activation of its receptor in various organs. This review suggest that GLP-1 receptor signaling helps prevent beta cell apoptosis and conserve function and morphology of human islet. The effect of GLP-1 signaling in weight loss in diabetic patients was proved by previous studies. The long term use of GLP-1 receptor agonists reduces cardiovascular and renal complications in diabetic patients. Significant evidence was found in previous literature for its effect on pancreatic secretions. The secretions of many enzymes and hormones, such as trypsin, lipase and glucagon, inhibited significantly while the increase in levels of insulin and somatostatin was reported in many studies. GLP-1 has a prominent role in cardiac functioning and increases the heart rate considerably. Based on the vast impact of GLP-1 on physiological functions, many GLP-1 receptor agonists can be made that can increase the healthy life span.</description><subject>Diabetes Complications - drug therapy</subject><subject>Diabetes Complications - metabolism</subject><subject>Diabetes Complications - prevention & control</subject><subject>Diabetes Mellitus - drug therapy</subject><subject>Diabetes Mellitus - metabolism</subject><subject>Glucagon-Like Peptide 1 - physiology</subject><subject>Glucagon-Like Peptide-1 Receptor - metabolism</subject><subject>Humans</subject><subject>Incretins - physiology</subject><subject>Insulin-Secreting Cells - cytology</subject><subject>Insulin-Secreting Cells - metabolism</subject><issn>0393-974X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j01LxDAUAHNQ3HX1L0iOHiwkeWnTeJNFd4WCHhS8ldfkVSP9iE2L7L9XcD3NZRiYE7YWYCGzRr-t2HlKn0Jo0MacsRUIAK2FXTPYVc-ZvOHI4_hNU7t0PH4cUhi78T047HgY3ERzGG45DnyJHme6YKctdokuj9yw14f7l-0-q552j9u7KotKyjlzrXIFGoGyEQW0gJbyQqEt0HtdlpIoLzUK6xok7RW6kprGu1wIpVolDWzY9V83TuPXQmmu-5AcdR0ONC6pVlKp3JQa4Fe9OqpL05Ov4xR6nA71_yj8ABRITSU</recordid><startdate>201809</startdate><enddate>201809</enddate><creator>Malik, J</creator><creator>Roohi, N</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201809</creationdate><title>GLP-1, a powerful physiological incretin: an update</title><author>Malik, J ; Roohi, N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-cf2c6a70a1b063f3a9e562a96add4881ee584a09cbae4d2ac8ebbdc50022f2173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Diabetes Complications - drug therapy</topic><topic>Diabetes Complications - metabolism</topic><topic>Diabetes Complications - prevention & control</topic><topic>Diabetes Mellitus - drug therapy</topic><topic>Diabetes Mellitus - metabolism</topic><topic>Glucagon-Like Peptide 1 - physiology</topic><topic>Glucagon-Like Peptide-1 Receptor - metabolism</topic><topic>Humans</topic><topic>Incretins - physiology</topic><topic>Insulin-Secreting Cells - cytology</topic><topic>Insulin-Secreting Cells - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Malik, J</creatorcontrib><creatorcontrib>Roohi, N</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of biological regulators and homeostatic agents</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Malik, J</au><au>Roohi, N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>GLP-1, a powerful physiological incretin: an update</atitle><jtitle>Journal of biological regulators and homeostatic agents</jtitle><addtitle>J Biol Regul Homeost Agents</addtitle><date>2018-09</date><risdate>2018</risdate><volume>32</volume><issue>5</issue><spage>1171</spage><epage>1176</epage><pages>1171-1176</pages><issn>0393-974X</issn><abstract>Food intake, especially carbohydrates, release incretin, which is an endocrine transmitter. Among the various endocrine modulators, Glucagon-like peptide 1 (GLP-1) is more effective in stimulating the release of insulin and more powerful regulator of physiological functions. Mainly (GLP-1) receptors are expressed in lungs, α and β cells of pancreatic islets and the nervous system. Peripheral tissues, gastrointestinal tract and extra pancreatic tissues i.e., vascular smooth muscle, kidney and heart, also contain high affinity receptors for GLP-1. The aim of this systematic review was to gather the available published evidence of the functions performed by GLP-1 through the activation of its receptor in various organs. This review suggest that GLP-1 receptor signaling helps prevent beta cell apoptosis and conserve function and morphology of human islet. The effect of GLP-1 signaling in weight loss in diabetic patients was proved by previous studies. The long term use of GLP-1 receptor agonists reduces cardiovascular and renal complications in diabetic patients. Significant evidence was found in previous literature for its effect on pancreatic secretions. The secretions of many enzymes and hormones, such as trypsin, lipase and glucagon, inhibited significantly while the increase in levels of insulin and somatostatin was reported in many studies. GLP-1 has a prominent role in cardiac functioning and increases the heart rate considerably. Based on the vast impact of GLP-1 on physiological functions, many GLP-1 receptor agonists can be made that can increase the healthy life span.</abstract><cop>Italy</cop><pmid>30334409</pmid><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0393-974X |
ispartof | Journal of biological regulators and homeostatic agents, 2018-09, Vol.32 (5), p.1171-1176 |
issn | 0393-974X |
language | eng |
recordid | cdi_proquest_miscellaneous_2122578433 |
source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
subjects | Diabetes Complications - drug therapy Diabetes Complications - metabolism Diabetes Complications - prevention & control Diabetes Mellitus - drug therapy Diabetes Mellitus - metabolism Glucagon-Like Peptide 1 - physiology Glucagon-Like Peptide-1 Receptor - metabolism Humans Incretins - physiology Insulin-Secreting Cells - cytology Insulin-Secreting Cells - metabolism |
title | GLP-1, a powerful physiological incretin: an update |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T08%3A10%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=GLP-1,%20a%20powerful%20physiological%20incretin:%20an%20update&rft.jtitle=Journal%20of%20biological%20regulators%20and%20homeostatic%20agents&rft.au=Malik,%20J&rft.date=2018-09&rft.volume=32&rft.issue=5&rft.spage=1171&rft.epage=1176&rft.pages=1171-1176&rft.issn=0393-974X&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E2122578433%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2122578433&rft_id=info:pmid/30334409&rfr_iscdi=true |